Abstract 6001
Abstract 6001 Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial. Marcia S. Brose, Bruce Robinson, Steven I. Sherman,…
Abstract 6000
Abstract 6000 Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial. Li Zhang, Yunpeng Yang, Song Qu, Jin-Gao Li,…
Abstract LBA2
Abstract LBA2 JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). Rui-hua Xu, Hai-Qiang Mai,…
Abstract 4500
Abstract 4500 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Brian I. Rini, Elizabeth…
Abstract 5000
Abstract 5000 A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First…
Abstract LBA5
Abstract LBA4 Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study. Toni K. Choueiri, Piotr Tomczak, Se Hoon Park,…
Abstract LBA4
Abstract LBA4 Phase 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). Michael J. Morris, Johann S. De Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz…
Abstract 3505
Abstract 3505 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). Takayuki Yoshino, Maria Di Bartolomeo,…
Abstract 3504
Abstract 3504 Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized…
Abstract LBA4001
Abstract LBA4001 Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate…